Monitoring and Communication Keep a symptom diary noting bowel movement frequency, consistency, and any associated symptoms
Researchers following protocols for weaning off tirzepatide who are planning to maintain berberine through the transition should be aware that blood glucose may rise as tirzepatide is reduced, potentially requiring upward berberine dose adjustment to maintain metabolic targets
This occurs because GLP-1 activation slows the movement of food from your stomach into your small intestine, triggering mild queasiness that typically peaks 23 days after injection and subsides within 12 weeks
Tirzepatide is supplied in single-dose prefilled pens with a hidden needle designed for subcutaneous injection
Symptoms of low blood sugar levels include dizziness, blurred vision, confusion, headache, shakiness, and even seizures and loss of consciousness in severe cases